This study is testing a medicine called olaparib for one or two years, with or without another medicine called bevacizumab, to treat ovarian cancer. Ovarian cancer happens in the ovaries, a part of the female body. Olaparib helps stop tumor cells from growing, while bevacizumab blocks blood vessels that help tumors grow. The study wants to see if taking these medicines can help people with a specific kind of ovarian cancer, called BRCA-mutated or HR-deficient ovarian cancer, live longer without the cancer growing back.
Key Points:
- Participants will be randomly assigned to take olaparib for either one year or two years.
- Some may also receive bevacizumab for one year, along with regular check-ups and scans.
- After the study treatment, follow-up visits will occur every 3 to 6 months for up to 5 years.
How understandable was the trial content above?
Hard to understand
Easy to understand